Lapatinib and Capecitabine for Second Line Treatment of Pancreas Cancer

PHASE2TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

December 31, 2012

Study Completion Date

June 30, 2013

Conditions

Pancreas Cancer

Interventions

DRUG

Lapatinib and Capecitabine

Lapatinib 1250-mg PO daily one hour before or after meals Capecitabine 1000 mg/m2 PO twice daily on days 1-14 of 21-day cycle for a total of 8 cycles

Trial Locations (1)

Georgetown University Medical Center, Washington D.C.